Pay in 4 interest-free payments of $6.47 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
The phase 3 trial is in 8,000+ patients with established cardiovascular disease and elevated Lp(a) with a hard primary endpoint composite of cardiovascular death, myocardial infarction, stroke, or urgent coronary revascularization requiring hospitalization
It potentially does so through its effects on serotonin uptake and antioxidant activity in the brain
Dosing tiers: Subcutaneous injection near the injury site delivers the fastest localized effect
Its use in jowls is considered off label but it is very effective in this region, and in the hands of an experienced physician it should be safe
US$ 26.06
US$ 23.61
US$ 29.89
US$ 21.56
